{"gene":"ADA","run_date":"2026-06-09T22:02:40","timeline":{"discoveries":[{"year":1985,"finding":"The E. coli Ada protein (38–39 kDa) transfers methyl groups from O6-methylguanine residues in alkylated DNA to its own cysteine residues, functioning as a suicidal methyltransferase; the protein comprises 354 amino acids and the promoter was mapped by S1 nuclease.","method":"Protein purification, in vitro methyltransferase assay, DNA sequencing, S1 nuclease mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro biochemical reconstitution of methyl-transfer activity with purified protein, replicated across multiple studies","pmids":["2987251"],"is_preprint":false},{"year":1985,"finding":"Ada protein acts as a positive autogenous regulator: cloned ada gene product induces expression of O6-methylguanine-DNA methyltransferase and 3-methyladenine-DNA glycosylase II even without alkylating agent treatment, and induction is strongly enhanced by methylating agents, demonstrating that the methylated Ada protein promotes transcription of its own gene.","method":"Cloning in multicopy plasmids, beta-galactosidase reporter (ada'-lacZ fusion), enzyme activity assays in vivo","journal":"Mutation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and reporter-based evidence replicated across labs; Ada protein's transcriptional activator role independently confirmed","pmids":["3929077"],"is_preprint":false},{"year":1982,"finding":"The ada mutation is in a regulatory locus controlling O6-methylguanine-DNA methyltransferase induction; ada mutants contain basal methyltransferase but cannot upregulate it upon alkylation treatment, showing Ada is required for the adaptive transcriptional response.","method":"In vitro enzyme assay with synthetic radiolabeled DNA substrate, comparison of wild-type and ada mutant strains","journal":"Journal of bacteriology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic loss-of-function with quantitative enzyme assay, single study","pmids":["6749819"],"is_preprint":false},{"year":1988,"finding":"Methylation of Ada protein at Cys-69 (by methyl phosphotriester transfer) converts Ada into a transcriptional activator; direct methylation of purified Ada protein by chemical methylating agents (methyl methanesulfonate, methyl iodide) also activates its ability to promote ada gene transcription in a reconstituted in vitro system.","method":"In vitro transcription reconstitution with purified methylated/unmethylated Ada protein","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified components demonstrating methylation-dependent transcriptional activation","pmids":["2843522"],"is_preprint":false},{"year":1988,"finding":"Ada protein expression is controlled by an ada regulatory sequence (AAAGCGCA) located upstream of the -35 box; both -10 and -35 promoter elements and this regulatory sequence are required for controlled ada expression. Methylated Ada protein is required for in vitro ada-specific transcription.","method":"Random and site-directed mutagenesis of ada promoter, deletion analysis, in vitro transcription","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis combined with in vitro transcription reconstitution","pmids":["3139888"],"is_preprint":false},{"year":1988,"finding":"Ada protein is cleaved by an endogenous E. coli thiol protease into a 20-kDa N-terminal fragment (which retains methylphosphotriester methyltransferase activity and can promote alkA but not ada transcription when methylated) and a 19-kDa C-terminal fragment (which retains O6-methylguanine methyltransferase activity); neither fragment alone promotes ada transcription.","method":"Partial purification of Ada-specific protease, proteolysis assay, activity assays on isolated fragments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical dissection of domain function with purified fragments and in vitro activity assays","pmids":["3058696"],"is_preprint":false},{"year":1989,"finding":"Methylated Ada protein binds the ada promoter (positions -63 to -31) including the AAAGCGCA regulatory sequence; non-methylated Ada does not bind stably. Methylation of Cys-69 (not Cys-321) is specifically required for Ada binding to the ada promoter and for facilitating subsequent RNA polymerase binding. The methylated Ada protein also allows RNA polymerase to bind properly, initiating transcription.","method":"DNase I footprinting, in vitro transcription with site-specific Ada mutants (Cys69Ala, Cys321Ala), promoter mutant analysis","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — footprinting + site-directed mutagenesis + in vitro transcription reconstitution in a single study","pmids":["2648001"],"is_preprint":false},{"year":1990,"finding":"The methylated 20-kDa N-terminal Ada fragment binds the alkA regulatory sequence and facilitates RNA polymerase binding to the alkA promoter, activating alkA transcription in vitro. The same methylated 20-kDa protein binds the ada promoter but does not support RNA polymerase binding there, thus acting as a repressor of ada transcription. Proteolytic cleavage of Ada terminates the adaptive response by removing the activator and generating a repressor.","method":"Overexpression of truncated Ada, in vitro transcription, in vivo reporter assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution plus in vivo confirmation, mechanistic model for adaptive response termination","pmids":["2254928"],"is_preprint":false},{"year":1990,"finding":"Ada protein binds DNA non-cooperatively; approximately 7 bp are covered per Ada monomer; binding is ionic in nature (equilibrium association constant decreases with increasing NaCl), as measured by fluorescence anisotropy.","method":"Fluorescence anisotropy of Ada protein upon DNA binding; quantitative binding analysis","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — rigorous biophysical assay on purified protein, single lab","pmids":["2354146"],"is_preprint":false},{"year":1993,"finding":"Methylated Ada protein is a class I transcription factor: it requires the C-terminal domain of the RNA polymerase alpha subunit for transcriptional activation, as demonstrated by loss of Ada-dependent activation with C-terminal-deleted alpha subunit mutant RNA polymerases.","method":"In vitro transcription with mutant RNA polymerases bearing C-terminal-deleted alpha subunits","journal":"Journal of bacteriology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro transcription with defined mutant components, clear mechanism","pmids":["8468304"],"is_preprint":false},{"year":1994,"finding":"Crystal structure of the 19-kDa C-terminal domain of E. coli Ada (Ada-C), the O6-methylguanine-DNA methyltransferase domain, shows the active-site cysteine is buried; a conformational change is proposed to allow DNA binding and methyl transfer.","method":"X-ray crystallography","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with atomic resolution; functionally validated by comparison with known mutant phenotypes","pmids":["8156986"],"is_preprint":false},{"year":1994,"finding":"Unmethylated Ada at physiologically relevant concentrations specifically inhibits methylated Ada activation of ada transcription (but not alkA transcription) both in vitro and in vivo; this requires the C-terminal 67 amino acids of Ada. This establishes Ada as both a positive and negative modulator of its own expression.","method":"In vitro transcription assay, in vivo reporter assays, C-terminal deletion mutants of Ada","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro and in vivo concordance, defined domain requirement, single lab","pmids":["7937881"],"is_preprint":false},{"year":1994,"finding":"In the methylated Ada protein–DNA complex, S-methylcysteine-69 (S-Me-Cys69) remains coordinated to the zinc ion; ligand exchange at the zinc center is not the mechanism for switching Ada from repair to transcriptional activator mode.","method":"Isotope-edited NMR (13C-labeled methyl group at Cys69), comparison of Zn- and Cd-substituted forms","journal":"Chemistry & biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural analysis with isotopic labeling, clear mechanistic conclusion, single lab","pmids":["9383376"],"is_preprint":false},{"year":1997,"finding":"Ada protein-dependent transcriptional activation at the ada and aidB promoters requires direct interaction between methylated Ada and the C-terminal domain of the RNA polymerase sigma70 subunit (amino acids 574–613); several negatively charged residues in sigma70 (notably Glu575) are critical. The alpha subunit C-terminal domain allows initial RNA polymerase binding, while sigma70 interaction drives activation.","method":"Deletion mutagenesis of RNA polymerase alpha and sigma subunits, in vitro transcription, site-directed mutagenesis of sigma70","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — defined protein–protein contact by mutagenesis plus functional in vitro transcription, multiple orthogonal approaches","pmids":["9582376"],"is_preprint":false},{"year":1997,"finding":"E. coli Ada-C protein can repair O6-benzylguanine in DNA, but very slowly compared to human alkyltransferase and E. coli Ogt; two active-site mutations (A316P and W336A) that enlarge the substrate-binding pocket of Ada-C greatly increase its reactivity with O6-benzylguanine, and DNA binding activates Ada-C for this reaction.","method":"Site-directed mutagenesis, in vitro alkyltransferase assay, substrate competition experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — active-site mutagenesis + in vitro assay with defined substrates, mechanistic interpretation of steric factors","pmids":["9079656"],"is_preprint":false},{"year":2001,"finding":"NMR solution structure of the N-terminal 10-kDa Ada domain (N-Ada10) reveals the zinc-thiolate center; EXAFS/XANES data confirm that S-Me-Cys69 remains coordinated to zinc upon methylation. The transferred methyl group makes contacts within N-Ada but not with DNA, implying that methylation induces a conformational change that remodels the protein surface to enhance promoter DNA binding without direct methyl-DNA contact.","method":"NMR structure determination, EXAFS/XANES spectroscopy, NOESY of labeled methylated Ada–DNA complexes","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal structural methods (NMR + X-ray absorption spectroscopy) in one study with functional interpretation","pmids":["11284682"],"is_preprint":false},{"year":2005,"finding":"X-ray and solution structures of the methylated N-terminal Ada chemosensor domain bound to DNA reveal that methyl phosphotriester repair and methylation-dependent transcriptional activation both operate through a zinc- and methylation-dependent electrostatic switch: methylation of Cys69 neutralizes a negative charge at the zinc center, converting a repulsive to an attractive interaction with DNA phosphates, thereby switching Ada from a repair protein to a transcriptional activator.","method":"X-ray crystallography and NMR of methylated N-Ada–DNA complex; functional validation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution structure with functional validation provides mechanistic model for the electrostatic switch","pmids":["16209950"],"is_preprint":false},{"year":1997,"finding":"In yeast, Gcn5 (which contains Ada protein homologs as subunits) functions as the catalytic histone acetyltransferase subunit in two distinct native complexes: the 0.8-MDa ADA complex and the 1.8-MDa SAGA complex. Both complexes contain Ada2 and can acetylate nucleosomal histones, unlike recombinant Gcn5 alone. The SAGA complex additionally contains Spt proteins linked to TBP function.","method":"Biochemical fractionation, histone acetyltransferase assays on free and nucleosomal histones, deletion mutant analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical reconstitution of HAT complexes with functional nucleosomal HAT assay; foundational study replicated by multiple labs","pmids":["9224714"],"is_preprint":false},{"year":1997,"finding":"Mutations in yeast ADA2, ADA3, and GCN5 (subunits of the Ada/histone acetyltransferase complex) cause phenotypes similar to swi/snf mutants and are required for expression of SWI/SNF-dependent genes; ada and swi1 double mutants are inviable; SIN1 mutations (chromatin component) or histone H3/H4 mutations partially suppress ada/swi defects, establishing that ADA/GCN5 and SWI/SNF complexes cooperate to antagonize chromatin-mediated repression.","method":"Yeast genetics, epistasis analysis, double mutant viability, partial purification of three GCN5-dependent acetyltransferase activities","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis across multiple loci plus biochemical acetyltransferase assays, replicated findings","pmids":["9343382"],"is_preprint":false},{"year":1998,"finding":"Tra1p is a component of yeast Ada/Spt transcriptional regulatory complexes; its association with Ada.Spt complexes was established by tandem mass spectrometry of Ngg1p/Ada3p co-purified proteins and confirmed by reciprocal co-immunoprecipitation of Ada2p and Tra1p. Tra1p co-fractionates with Ngg1p and Spt7p; binding of Tra1p to DNA-cellulose requires Ada components.","method":"Tandem mass spectrometry, reciprocal co-immunoprecipitation, sequential chromatography","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus MS identification, single lab, multiple orthogonal methods","pmids":["9756893"],"is_preprint":false},{"year":1999,"finding":"The yeast ADA complex (0.8 MDa) is a distinct histone acetyltransferase complex separate from SAGA, containing Ada2, Ada3, Gcn5, and a novel unique subunit Ahc1 (product of YOR023C); deletion of AHC1 disrupts ADA complex integrity without affecting SAGA, demonstrating that ADA is not merely a SAGA subcomplex.","method":"10-step chromatographic purification, mass spectrometry, immunoblotting, deletion mutant analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — extensive biochemical purification combined with MS identification and genetic validation","pmids":["10490601"],"is_preprint":false},{"year":1997,"finding":"The yeast Ada adaptor complex is important for glucocorticoid receptor (GR)-mediated gene activation; Ada2 directly binds the GR tau1c transactivation domain in vitro using purified proteins and GST-pulldown, and this interaction is reduced by a mutation that reduces tau1c transactivation.","method":"Yeast genetics (ada mutant phenotype), GST pulldown with purified proteins, in vitro protein-protein interaction","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein interaction confirmed with purified proteins, functional genetic data, single lab","pmids":["9154805"],"is_preprint":false},{"year":2000,"finding":"In yeast, GCN5, ADA2, ADA1, and ADA3 are required for T3/GRIP1 or SRC-1 coactivator-dependent transcriptional activation by human thyroid hormone receptor beta1 (hTRbeta1); hTRbeta1 binds directly to yeast or human GCN5 and to hADA2 in vitro; T3-dependent binding of hTRbeta1 to hGCN5 is enhanced by GRIP1 or SRC-1. The HAT domain and bromodomain of GCN5 must be intact for maximal activation.","method":"Yeast genetic epistasis, in vitro protein-protein interaction (GST pulldown with purified proteins), mutagenesis of GRIP1 LXXLL motifs","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast genetics plus direct protein binding with purified proteins, single lab","pmids":["10809234"],"is_preprint":false},{"year":2015,"finding":"In metazoans, GCN5 is incorporated into two distinct HAT complexes: ATAC (containing ADA2a) and SAGA (containing ADA2b). The subunit environment determines GCN5 catalytic activity: all tested GCN5-containing complexes acetylate mainly histone H3K14, but ADA2b has a stronger stimulatory influence on GCN5 activity than ADA2a. Incorporation into holo-complexes further increases GCN5 activity beyond the HAT module alone.","method":"In vitro HAT assay with purified recombinant and endogenous ATAC/SAGA HAT modules and holo-complexes using histone peptides and full-length histones","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified recombinant complexes and multiple substrates, single lab but multiple orthogonal readouts","pmids":["26468280"],"is_preprint":false},{"year":2015,"finding":"The SAGA complex adopts three major conformations; the acetyltransferase module is localized in the most mobile region. Cross-linking mass spectrometry mapped comprehensive subunit interconnectivity, showing that Spt and Taf subunits form the structural core, and chromatin-binding domains cluster on one flexible face.","method":"Gradient fixation, single-particle EM (2D and 3D), EM-based subunit labeling, cross-linking mass spectrometry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structural analysis plus cross-linking MS, multiple orthogonal methods in one study","pmids":["25713136"],"is_preprint":false},{"year":2011,"finding":"In ADA-deficient mice, Tregs show alterations in plasma membrane CD39/CD73 ectonucleotidase machinery and have limited suppressive activity via extracellular adenosine; ADA deficiency causes loss of Treg function contributing to autoimmunity. PEG-ADA-treated mice develop autoantibodies and hypothyroidism and have Tregs lacking suppressive activity, whereas bone marrow transplantation or gene therapy corrects Treg function.","method":"Functional Treg suppression assays, flow cytometry, mouse genetic models (ADA-/- mice), treatment comparisons (PEG-ADA, BMT, gene therapy)","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional suppression assays in defined genetic model with multiple therapeutic comparisons, single lab","pmids":["22184407"],"is_preprint":false},{"year":2009,"finding":"ADA deficiency in mice causes a bone phenotype resulting from RANKL/OPG axis imbalance (decreased osteoclastogenesis) and intrinsic osteoblast dysfunction (reduced bone formation); ADA-deficient osteoblasts in vitro show altered transcriptional profile and growth reduction. Treatment with ERT, BMT, or gene therapy fully rescues the bone phenotype.","method":"Mouse genetic model (ADA-/- mice), structural bone analysis, in vitro osteoblast culture, RANKL/OPG quantification, treatment rescue experiments","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined genetic model with in vitro mechanistic follow-up and multiple treatment rescues, single lab","pmids":["19633200"],"is_preprint":false},{"year":2008,"finding":"In ADA-SCID patients, ADA substrate accumulation causes impaired TCR/CD28-driven T-cell proliferation and cytokine production associated with reduced ZAP-70 phosphorylation, Ca2+ flux, and ERK1/2 signaling, and defective CREB and NF-κB transcriptional activity. Exposure to 2'-deoxyadenosine further inhibits T-cell activation via A2A adenosine receptor/PKA hyperactivation. Gene therapy restores normal TCR signaling in patient T cells.","method":"Phosphoprotein analysis, calcium flux assay, cytokine measurement, patient T cells vs. gene-therapy-corrected T cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient-derived cells with multiple signaling readouts and gene-therapy correction as functional rescue, single lab","pmids":["18218852"],"is_preprint":false},{"year":2017,"finding":"In ADA-deficient mice, metabolic alterations in the brain include aberrant adenosine receptor signaling; PEG-ADA corrects metabolic adenosine-based alterations but not cellular and signaling defects, indicating an intrinsic neurological component to ADA deficiency separate from circulating adenosine levels.","method":"Behavioral testing, molecular/metabolic analyses, treatment with PEG-ADA vs. untreated ADA-/- mice","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mouse genetic model with molecular mechanistic analysis, single lab","pmids":["28074903"],"is_preprint":false},{"year":1990,"finding":"The B. subtilis ada operon encodes two separate DNA alkyltransferases: AdaA (methylphosphotriester-DNA methyltransferase) functioning as a transcriptional activator of the ada operon, and AdaB (O6-methylguanine-DNA methyltransferase) functioning specifically in repair of mutagenic O6-methylguanine; the two genes overlap by 11 bp and are co-induced by MNNG.","method":"Complementation of ada mutants, gene cloning, transcript analysis, functional dissection of truncated constructs","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic complementation with functional domain analysis; describes bacterial ortholog mechanism","pmids":["2120677"],"is_preprint":false}],"current_model":"The E. coli Ada protein is a bifunctional enzyme and transcriptional regulator of the adaptive response to alkylating agents: its C-terminal domain irreversibly transfers methyl groups from O6-methylguanine in DNA to Cys-321, while its N-terminal domain transfers methyl from methylphosphotriesters to Cys-69; methylation at Cys-69 triggers an electrostatic switch—maintaining zinc-thiolate coordination but remodeling a surface patch—that converts Ada into a sequence-specific transcriptional activator that binds the ada/alkA promoters and recruits RNA polymerase through direct contact with the sigma70 C-terminal domain, while unmethylated Ada and a proteolytic 20-kDa fragment act as negative regulators to terminate the response; in eukaryotes, the orthologous ADA complex subunits (Ada2, Ada3) scaffold the GCN5 histone acetyltransferase within the ADA and SAGA co-activator complexes to acetylate nucleosomal histone H3K14 and mediate transcriptional activation by nuclear receptors, with complex-specific ADA2 isoforms (ADA2a in ATAC, ADA2b in SAGA) differentially stimulating GCN5 catalytic activity; in humans, ADA enzymatic activity (deamination of adenosine and deoxyadenosine) is essential for lymphocyte survival, and its deficiency causes toxic purine metabolite accumulation that impairs TCR signaling, Treg function via the CD39/CD73/adenosine axis, bone homeostasis via RANKL/OPG imbalance, and brain adenosine receptor signaling."},"narrative":{"mechanistic_narrative":"The ADA symbol in this corpus resolves into three biologically distinct proteins, and the timeline is dominated by the bacterial Ada DNA-alkylation-repair regulator rather than the human adenosine deaminase. The E. coli Ada protein is a bifunctional suicide methyltransferase that, in its repair role, irreversibly transfers methyl groups from O6-methylguanine in alkylated DNA to its own cysteine residues [PMID:2987251], with the active-site cysteine buried in the 19-kDa C-terminal domain whose structure has been solved [PMID:8156986]. A second methyltransferase activity in the N-terminal domain accepts methyl from methylphosphotriesters at Cys-69, and this specific modification—not the C-terminal Cys-321 methylation—converts Ada into a sequence-specific transcriptional activator of the adaptive response to alkylating agents [PMID:2843522, PMID:2648001]. Methylated Ada binds the ada/alkA regulatory sequence (AAAGCGCA) upstream of the promoter and recruits RNA polymerase through direct contact with the C-terminal domain of the alpha subunit and with the C-terminal region of sigma70 (notably Glu575), defining Ada as a class I activator [PMID:3139888, PMID:8468304, PMID:9582376]. The repair-to-activator switch is electrostatic rather than ligand-exchange-based: structural and spectroscopic analyses show S-methyl-Cys69 remains zinc-coordinated, and neutralization of negative charge at the zinc-thiolate center remodels a surface patch to convert phosphate repulsion into attraction for promoter DNA [PMID:9383376, PMID:11284682, PMID:16209950]. The response is self-limiting: unmethylated Ada antagonizes its own activation [PMID:7937881], and an endogenous protease cleaves Ada into a 20-kDa N-terminal fragment that activates alkA but represses ada, terminating the adaptive response [PMID:3058696, PMID:2254928]. A separate set of findings describes the eukaryotic ADA/Ada2/Ada3 transcriptional co-activator subunits, which scaffold the GCN5 histone acetyltransferase within the ADA and SAGA complexes to acetylate nucleosomal histone H3K14, antagonize chromatin-mediated repression together with SWI/SNF, and mediate activation by nuclear receptors, with complex-specific ADA2 isoforms (ATAC ADA2a vs SAGA ADA2b) differentially stimulating GCN5 [PMID:9224714, PMID:9343382, PMID:26468280]. A third set addresses human ADA enzymatic activity, whose deficiency causes toxic purine accumulation impairing TCR signaling [PMID:18218852], Treg suppressive function via the CD39/CD73/adenosine axis [PMID:22184407], bone homeostasis via RANKL/OPG imbalance [PMID:19633200], and brain adenosine receptor signaling [PMID:28074903]. These three groups describe unrelated proteins sharing the ADA/Ada symbol.","teleology":[{"year":1982,"claim":"Established that Ada is a regulatory locus required for the inducible adaptive response, not merely the repair enzyme itself, since ada mutants retain basal methyltransferase but cannot upregulate it.","evidence":"In vitro enzyme assay on radiolabeled DNA comparing wild-type and ada mutant E. coli strains","pmids":["6749819"],"confidence":"Medium","gaps":["Did not define the molecular activity of the Ada gene product","Single genetic study without biochemical mechanism"]},{"year":1985,"claim":"Defined Ada as a suicidal methyltransferase that transfers methyl from O6-methylguanine to its own cysteines, identifying the repair chemistry and protein.","evidence":"Protein purification, in vitro methyltransferase assay, DNA sequencing and S1 mapping in E. coli","pmids":["2987251","3929077"],"confidence":"High","gaps":["Did not resolve which cysteine accepts which methyl group","Mechanism linking methylation to transcription not established"]},{"year":1988,"claim":"Showed that methylation of Cys-69 by methylphosphotriester transfer—reproducible with chemical methylating agents—converts Ada into a transcriptional activator, mechanistically coupling DNA damage sensing to gene induction.","evidence":"In vitro transcription reconstitution and promoter mutagenesis with purified methylated/unmethylated Ada","pmids":["2843522","3139888"],"confidence":"High","gaps":["Direct DNA binding by methylated Ada not yet demonstrated","RNA polymerase contacts undefined"]},{"year":1989,"claim":"Demonstrated that methylated Ada binds the ada promoter regulatory sequence and facilitates RNA polymerase binding, and that Cys-69 (not Cys-321) methylation is specifically required, separating the repair and regulatory functions.","evidence":"DNase I footprinting and in vitro transcription with Cys69Ala/Cys321Ala site-directed mutants","pmids":["2648001"],"confidence":"High","gaps":["Biophysical nature of DNA binding not quantified","Specific RNA polymerase subunit contacts not mapped"]},{"year":1990,"claim":"Established the self-limiting architecture of the response: proteolytic cleavage removes the ada activator and generates a 20-kDa fragment that activates alkA but represses ada, terminating the adaptive response; DNA binding was also characterized biophysically.","evidence":"Truncated Ada overexpression, in vitro transcription, in vivo reporters, and fluorescence anisotropy DNA-binding analysis","pmids":["2254928","2354146"],"confidence":"High","gaps":["Identity and regulation of the endogenous protease not fully defined","Structural basis of differential ada vs alkA promoter behavior unresolved"]},{"year":1994,"claim":"Refined the regulatory logic by showing unmethylated Ada antagonizes methylated-Ada activation of ada (requiring the C-terminal 67 residues), establishing Ada as both positive and negative modulator of its own expression.","evidence":"In vitro and in vivo transcription assays with C-terminal deletion mutants of Ada","pmids":["7937881"],"confidence":"High","gaps":["Structural basis of the inhibitory interaction not defined","Promoter-specificity of inhibition mechanism unexplained"]},{"year":1993,"claim":"Identified Ada as a class I transcription factor requiring the RNA polymerase alpha C-terminal domain, then mapped a direct activating contact with the sigma70 C-terminal region (Glu575), defining the activation interface.","evidence":"In vitro transcription with alpha- and sigma-subunit deletion and point mutants","pmids":["8468304","9582376"],"confidence":"High","gaps":["Atomic structure of the Ada–RNA polymerase contact not solved","Stoichiometry of the activation complex unknown"]},{"year":1994,"claim":"Resolved the switch mechanism structurally, showing methylated Cys-69 remains zinc-coordinated and that ligand exchange at zinc is not the switch, and solved the C-terminal repair domain structure revealing a buried active-site cysteine.","evidence":"Isotope-edited NMR of 13C-methyl-Cys69, Zn/Cd substitution, and X-ray crystallography of Ada-C","pmids":["9383376","8156986"],"confidence":"High","gaps":["How surface remodeling enables DNA binding not yet visualized","Conformational change enabling repair-domain DNA access only proposed"]},{"year":1997,"claim":"Characterized the repair domain's substrate determinants, showing active-site steric mutations (A316P, W336A) expand reactivity toward O6-benzylguanine and that DNA binding activates Ada-C.","evidence":"Active-site site-directed mutagenesis and in vitro alkyltransferase assays with defined substrates","pmids":["9079656"],"confidence":"High","gaps":["Physiological relevance of expanded substrate range unaddressed","Coupling of DNA binding to catalysis not structurally resolved"]},{"year":2005,"claim":"Provided the definitive electrostatic-switch model: structures of methylated N-Ada bound to DNA show Cys69 methylation neutralizes negative charge at the zinc center, converting phosphate repulsion to attraction and unifying repair and transcriptional functions.","evidence":"X-ray and NMR structures of methylated N-Ada–DNA complex with EXAFS/XANES and functional validation","pmids":["16209950","11284682"],"confidence":"High","gaps":["Full-length Ada–promoter–RNA polymerase assembly structure not determined","Dynamics of the surface remodeling not characterized"]},{"year":1999,"claim":"Established that eukaryotic Ada2/Ada3 subunits scaffold GCN5 into distinct nucleosome-acetylating complexes (ADA and SAGA), conferring nucleosomal HAT activity absent in free GCN5 and revealing ADA as a bona fide separate complex via the Ahc1 subunit.","evidence":"Biochemical fractionation, nucleosomal HAT assays, MS identification, and deletion analysis in yeast","pmids":["9224714","10490601"],"confidence":"High","gaps":["These findings concern a distinct protein from bacterial Ada sharing the symbol","Mechanism by which Ada subunits stimulate GCN5 not defined here"]},{"year":2000,"claim":"Linked the ADA/GCN5 co-activator subunits to chromatin antagonism with SWI/SNF and to nuclear receptor activation (glucocorticoid and thyroid hormone receptors) through direct Ada2/GCN5 contacts.","evidence":"Yeast genetic epistasis, GST pulldowns with purified proteins, and HAT assays","pmids":["9343382","9154805","10809234"],"confidence":"Medium","gaps":["Direct receptor-Ada2 interactions shown in single labs","Concerns the eukaryotic ADA co-activator, distinct from bacterial Ada and human adenosine deaminase"]},{"year":2015,"claim":"Defined how metazoan complex context tunes GCN5: ATAC (ADA2a) and SAGA (ADA2b) both target H3K14 but ADA2b stimulates GCN5 more strongly, and holo-complex incorporation further boosts activity, with SAGA architecture mapped structurally.","evidence":"In vitro HAT assays with reconstituted modules/holo-complexes and cryo-EM plus cross-linking MS","pmids":["26468280","25713136"],"confidence":"High","gaps":["Mechanism of differential ADA2a vs ADA2b stimulation not structurally resolved","Distinct protein from the human adenosine deaminase ADA"]},{"year":2017,"claim":"Established the physiological consequences of human ADA enzymatic deficiency across systems—T-cell receptor signaling, Treg suppressive function, bone homeostasis, and brain adenosine signaling—via toxic purine/adenosine accumulation.","evidence":"ADA-deficient mouse models and patient-derived T cells with signaling, suppression, bone, and metabolic readouts plus therapeutic rescue (ERT/BMT/gene therapy)","pmids":["18218852","22184407","19633200","28074903"],"confidence":"Medium","gaps":["These describe human adenosine deaminase, a distinct enzyme from the bacterial/eukaryotic Ada in this corpus","Intrinsic versus adenosine-mediated contributions only partially separated"]},{"year":null,"claim":"It remains unresolved how the full bacterial Ada–promoter–RNA polymerase activation complex is structurally assembled and how the surface electrostatic switch is communicated to the holoenzyme; the corpus also conflates three distinct ADA/Ada proteins.","evidence":"","pmids":[],"confidence":"Low","gaps":["No atomic structure of the activator-bound transcription initiation complex","Symbol collision among bacterial Ada repair regulator, eukaryotic ADA co-activator subunit, and human adenosine deaminase"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[0,5,10,14]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,3,5]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[6,8,16]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,3,6,9]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[17,23]}],"localization":[],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,10]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,6,9,13]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[17,18,23]}],"complexes":["SAGA","ADA complex","ATAC"],"partners":["GCN5","ADA2","ADA3","TRA1","SPT7"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P00813","full_name":"Adenosine deaminase","aliases":["Adenosine aminohydrolase"],"length_aa":363,"mass_kda":40.8,"function":"Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine (PubMed:16670267, PubMed:23193172, PubMed:26166670, PubMed:8452534, PubMed:9361033). Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4 (PubMed:20959412). Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion (PubMed:11772392). Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion (By similarity). Enhances CD4+ T-cell differentiation and proliferation (PubMed:20959412). Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change (PubMed:23193172). Stimulates plasminogen activation (PubMed:15016824). Plays a role in male fertility (PubMed:21919946, PubMed:26166670). Plays a protective role in early postimplantation embryonic development (By similarity). Also responsible for the deamination of cordycepin (3'-deoxyadenosine), a fungal natural product that shows antitumor, antibacterial, antifungal, antivirus, and immune regulation properties (PubMed:26038697)","subcellular_location":"Cell membrane; Cell junction; Cytoplasmic vesicle lumen; Cytoplasm; Lysosome","url":"https://www.uniprot.org/uniprotkb/P00813/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADA","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADA","total_profiled":1310},"omim":[{"mim_id":"619952","title":"TRANSMEMBRANE PROTEIN 63B; TMEM63B","url":"https://www.omim.org/entry/619952"},{"mim_id":"619346","title":"ADENOSINE DEAMINASE-LIKE PROTEIN; ADAL","url":"https://www.omim.org/entry/619346"},{"mim_id":"618310","title":"DIAMOND-BLACKFAN ANEMIA 18; DBA18","url":"https://www.omim.org/entry/618310"},{"mim_id":"615688","title":"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME; VAIHS","url":"https://www.omim.org/entry/615688"},{"mim_id":"613938","title":"PARASOMNIA, SLEEPWALKING TYPE; PSMNSW","url":"https://www.omim.org/entry/613938"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":454.0},{"tissue":"lymphoid tissue","ntpm":228.3}],"url":"https://www.proteinatlas.org/search/ADA"},"hgnc":{"alias_symbol":["ADA1"],"prev_symbol":[]},"alphafold":{"accession":"P00813","domains":[{"cath_id":"3.20.20.140","chopping":"10-354","consensus_level":"high","plddt":98.2289,"start":10,"end":354}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P00813","model_url":"https://alphafold.ebi.ac.uk/files/AF-P00813-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P00813-F1-predicted_aligned_error_v6.png","plddt_mean":96.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADA","jax_strain_url":"https://www.jax.org/strain/search?query=ADA"},"sequence":{"accession":"P00813","fasta_url":"https://rest.uniprot.org/uniprotkb/P00813.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P00813/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P00813"}},"corpus_meta":[{"pmid":"30291106","id":"PMC_30291106","title":"Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2018","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/30291106","citation_count":1940,"is_preprint":false},{"pmid":"36148880","id":"PMC_36148880","title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2022","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/36148880","citation_count":1303,"is_preprint":false},{"pmid":"9224714","id":"PMC_9224714","title":"Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complex.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9224714","citation_count":927,"is_preprint":false},{"pmid":"12089448","id":"PMC_12089448","title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.","date":"2002","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12089448","citation_count":873,"is_preprint":false},{"pmid":"31857443","id":"PMC_31857443","title":"2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2019","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/31857443","citation_count":858,"is_preprint":false},{"pmid":"25249672","id":"PMC_25249672","title":"Diabetic kidney disease: a report from an ADA Consensus Conference.","date":"2014","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/25249672","citation_count":850,"is_preprint":false},{"pmid":"30288571","id":"PMC_30288571","title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2018","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/30288571","citation_count":809,"is_preprint":false},{"pmid":"36151309","id":"PMC_36151309","title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2022","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/36151309","citation_count":688,"is_preprint":false},{"pmid":"36189689","id":"PMC_36189689","title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).","date":"2022","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/36189689","citation_count":597,"is_preprint":false},{"pmid":"7570000","id":"PMC_7570000","title":"Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7570000","citation_count":580,"is_preprint":false},{"pmid":"25257325","id":"PMC_25257325","title":"Diabetic kidney disease: a report from an ADA Consensus Conference.","date":"2014","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/25257325","citation_count":446,"is_preprint":false},{"pmid":"31853556","id":"PMC_31853556","title":"2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","date":"2020","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/31853556","citation_count":346,"is_preprint":false},{"pmid":"9662367","id":"PMC_9662367","title":"T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.","date":"1998","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9662367","citation_count":250,"is_preprint":false},{"pmid":"36202661","id":"PMC_36202661","title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).","date":"2022","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/36202661","citation_count":218,"is_preprint":false},{"pmid":"17671653","id":"PMC_17671653","title":"Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17671653","citation_count":198,"is_preprint":false},{"pmid":"9343382","id":"PMC_9343382","title":"Role for ADA/GCN5 products in antagonizing chromatin-mediated transcriptional repression.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9343382","citation_count":187,"is_preprint":false},{"pmid":"28396566","id":"PMC_28396566","title":"Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products.","date":"2017","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28396566","citation_count":184,"is_preprint":false},{"pmid":"8156986","id":"PMC_8156986","title":"Crystal structure of a suicidal DNA repair protein: the Ada O6-methylguanine-DNA methyltransferase from E. coli.","date":"1994","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8156986","citation_count":176,"is_preprint":false},{"pmid":"19638621","id":"PMC_19638621","title":"How I treat ADA deficiency.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19638621","citation_count":164,"is_preprint":false},{"pmid":"10490601","id":"PMC_10490601","title":"The ADA complex is a distinct histone acetyltransferase complex in Saccharomyces cerevisiae.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10490601","citation_count":156,"is_preprint":false},{"pmid":"2987251","id":"PMC_2987251","title":"Purification and structure of the intact Ada regulatory protein of Escherichia coli K12, O6-methylguanine-DNA methyltransferase.","date":"1985","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2987251","citation_count":129,"is_preprint":false},{"pmid":"9756893","id":"PMC_9756893","title":"Tra1p is a component of the yeast Ada.Spt transcriptional regulatory complexes.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9756893","citation_count":113,"is_preprint":false},{"pmid":"30586775","id":"PMC_30586775","title":"Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","date":"2018","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/30586775","citation_count":94,"is_preprint":false},{"pmid":"2081198","id":"PMC_2081198","title":"The ADA human gene therapy clinical protocol.","date":"1990","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/2081198","citation_count":89,"is_preprint":false},{"pmid":"30423394","id":"PMC_30423394","title":"Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","date":"2018","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30423394","citation_count":89,"is_preprint":false},{"pmid":"28842866","id":"PMC_28842866","title":"Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.","date":"2017","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28842866","citation_count":81,"is_preprint":false},{"pmid":"14726805","id":"PMC_14726805","title":"Mutations in genes required for T-cell development: IL7R, CD45, IL2RG, JAK3, RAG1, RAG2, ARTEMIS, and ADA and severe combined immunodeficiency: HuGE review.","date":"2004","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14726805","citation_count":81,"is_preprint":false},{"pmid":"22184407","id":"PMC_22184407","title":"Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22184407","citation_count":79,"is_preprint":false},{"pmid":"2549545","id":"PMC_2549545","title":"Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells.","date":"1989","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2549545","citation_count":76,"is_preprint":false},{"pmid":"28847159","id":"PMC_28847159","title":"Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.","date":"2017","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28847159","citation_count":70,"is_preprint":false},{"pmid":"6749819","id":"PMC_6749819","title":"O6-methylguanine-DNA methyltransferase in wild-type and ada mutants of Escherichia coli.","date":"1982","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/6749819","citation_count":67,"is_preprint":false},{"pmid":"16209950","id":"PMC_16209950","title":"A methylation-dependent electrostatic switch controls DNA repair and transcriptional activation by E. coli ada.","date":"2005","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16209950","citation_count":66,"is_preprint":false},{"pmid":"16835374","id":"PMC_16835374","title":"Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16835374","citation_count":63,"is_preprint":false},{"pmid":"19633200","id":"PMC_19633200","title":"ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19633200","citation_count":61,"is_preprint":false},{"pmid":"9154805","id":"PMC_9154805","title":"Role of the Ada adaptor complex in gene activation by the glucocorticoid receptor.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9154805","citation_count":58,"is_preprint":false},{"pmid":"18218852","id":"PMC_18218852","title":"Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18218852","citation_count":58,"is_preprint":false},{"pmid":"23796864","id":"PMC_23796864","title":"Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy.","date":"2013","source":"The Journal of infection","url":"https://pubmed.ncbi.nlm.nih.gov/23796864","citation_count":55,"is_preprint":false},{"pmid":"2120677","id":"PMC_2120677","title":"Bacillus subtilis ada operon encodes two DNA alkyltransferases.","date":"1990","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2120677","citation_count":54,"is_preprint":false},{"pmid":"1904855","id":"PMC_1904855","title":"Cloning and characterization of the Salmonella typhimurium ada gene, which encodes O6-methylguanine-DNA methyltransferase.","date":"1991","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/1904855","citation_count":51,"is_preprint":false},{"pmid":"9079656","id":"PMC_9079656","title":"Repair of O6-benzylguanine by the Escherichia coli Ada and Ogt and the human O6-alkylguanine-DNA alkyltransferases.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9079656","citation_count":50,"is_preprint":false},{"pmid":"16651028","id":"PMC_16651028","title":"In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.","date":"2006","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16651028","citation_count":50,"is_preprint":false},{"pmid":"10809234","id":"PMC_10809234","title":"GCN5 and ADA adaptor proteins regulate triiodothyronine/GRIP1 and SRC-1 coactivator-dependent gene activation by the human thyroid hormone receptor.","date":"2000","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/10809234","citation_count":49,"is_preprint":false},{"pmid":"25713136","id":"PMC_25713136","title":"Conformational flexibility and subunit arrangement of the modular yeast Spt-Ada-Gcn5 acetyltransferase complex.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25713136","citation_count":49,"is_preprint":false},{"pmid":"3323828","id":"PMC_3323828","title":"DNA base changes induced following in vivo exposure of unadapted, adapted or ada- Escherichia coli to N-methyl-N'-nitro-N-nitrosoguanidine.","date":"1987","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/3323828","citation_count":49,"is_preprint":false},{"pmid":"35671392","id":"PMC_35671392","title":"Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35671392","citation_count":48,"is_preprint":false},{"pmid":"2648001","id":"PMC_2648001","title":"Regulation of expression of the ada gene controlling the adaptive response. Interactions with the ada promoter of the Ada protein and RNA polymerase.","date":"1989","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2648001","citation_count":48,"is_preprint":false},{"pmid":"26468280","id":"PMC_26468280","title":"Subunits of ADA-two-A-containing (ATAC) or Spt-Ada-Gcn5-acetyltrasferase (SAGA) Coactivator Complexes Enhance the Acetyltransferase Activity of GCN5.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26468280","citation_count":45,"is_preprint":false},{"pmid":"2254928","id":"PMC_2254928","title":"Positive and negative regulation of transcription by a cleavage product of Ada protein.","date":"1990","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2254928","citation_count":44,"is_preprint":false},{"pmid":"7749407","id":"PMC_7749407","title":"PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency.","date":"1995","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/7749407","citation_count":41,"is_preprint":false},{"pmid":"2682522","id":"PMC_2682522","title":"Expression of the ogt gene in wild-type and ada mutants of E. coli.","date":"1989","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2682522","citation_count":39,"is_preprint":false},{"pmid":"28074903","id":"PMC_28074903","title":"Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28074903","citation_count":39,"is_preprint":false},{"pmid":"8399494","id":"PMC_8399494","title":"Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.","date":"1993","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/8399494","citation_count":39,"is_preprint":false},{"pmid":"33046093","id":"PMC_33046093","title":"Characterization of total adenosine deaminase activity (ADA) and its isoenzymes in saliva and serum in health and inflammatory conditions in four different species: an analytical and clinical validation pilot study.","date":"2020","source":"BMC veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/33046093","citation_count":39,"is_preprint":false},{"pmid":"3139888","id":"PMC_3139888","title":"Expression of the ada gene of Escherichia coli in response to alkylating agents. Identification of transcriptional regulatory elements.","date":"1988","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3139888","citation_count":37,"is_preprint":false},{"pmid":"1325209","id":"PMC_1325209","title":"Transfer of the ADA gene into human ADA-deficient T lymphocytes reconstitutes specific immune functions.","date":"1992","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1325209","citation_count":36,"is_preprint":false},{"pmid":"3929077","id":"PMC_3929077","title":"Regulation of expression of the cloned ada gene in Escherichia coli.","date":"1985","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/3929077","citation_count":36,"is_preprint":false},{"pmid":"7937881","id":"PMC_7937881","title":"The Ada protein acts as both a positive and a negative modulator of Escherichia coli's response to methylating agents.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7937881","citation_count":36,"is_preprint":false},{"pmid":"28194615","id":"PMC_28194615","title":"How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).","date":"2017","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28194615","citation_count":34,"is_preprint":false},{"pmid":"2354146","id":"PMC_2354146","title":"Interaction of Ada protein with DNA examined by fluorescence anisotropy of the protein.","date":"1990","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2354146","citation_count":34,"is_preprint":false},{"pmid":"27034966","id":"PMC_27034966","title":"Development of Immunocapture-LC/MS Assay for Simultaneous ADA Isotyping and Semiquantitation.","date":"2016","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/27034966","citation_count":34,"is_preprint":false},{"pmid":"9582376","id":"PMC_9582376","title":"Ada protein-RNA polymerase sigma subunit interaction and alpha subunit-promoter DNA interaction are necessary at different steps in transcription initiation at the Escherichia coli Ada and aidB promoters.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9582376","citation_count":34,"is_preprint":false},{"pmid":"35578991","id":"PMC_35578991","title":"2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness (Part 3 - Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization).","date":"2022","source":"Bioanalysis","url":"https://pubmed.ncbi.nlm.nih.gov/35578991","citation_count":33,"is_preprint":false},{"pmid":"22833548","id":"PMC_22833548","title":"Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22833548","citation_count":33,"is_preprint":false},{"pmid":"24810496","id":"PMC_24810496","title":"Ada response - a strategy for repair of alkylated DNA in bacteria.","date":"2014","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24810496","citation_count":30,"is_preprint":false},{"pmid":"28655782","id":"PMC_28655782","title":"ADA-07 Suppresses Solar Ultraviolet-Induced Skin Carcinogenesis by Directly Inhibiting TOPK.","date":"2017","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28655782","citation_count":30,"is_preprint":false},{"pmid":"24076575","id":"PMC_24076575","title":"The inclusion of ADA-SCID in expanded newborn screening by tandem mass spectrometry.","date":"2013","source":"Journal of pharmaceutical and biomedical analysis","url":"https://pubmed.ncbi.nlm.nih.gov/24076575","citation_count":30,"is_preprint":false},{"pmid":"8376346","id":"PMC_8376346","title":"Bacillus subtilis alkA gene encoding inducible 3-methyladenine DNA glycosylase is adjacent to the ada operon.","date":"1993","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/8376346","citation_count":29,"is_preprint":false},{"pmid":"38185066","id":"PMC_38185066","title":"A new andrographolide derivative ADA targeting SIRT3-FOXO3a signaling mitigates cognitive impairment by activating mitophagy and inhibiting neuroinflammation in Apoe4 mice.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38185066","citation_count":28,"is_preprint":false},{"pmid":"29744787","id":"PMC_29744787","title":"ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.","date":"2018","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29744787","citation_count":28,"is_preprint":false},{"pmid":"36582120","id":"PMC_36582120","title":"Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.","date":"2023","source":"European journal of preventive cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/36582120","citation_count":28,"is_preprint":false},{"pmid":"17823664","id":"PMC_17823664","title":"Bacterial DNA repair genes and their eukaryotic homologues: 3. AlkB dioxygenase and Ada methyltransferase in the direct repair of alkylated DNA.","date":"2007","source":"Acta biochimica Polonica","url":"https://pubmed.ncbi.nlm.nih.gov/17823664","citation_count":28,"is_preprint":false},{"pmid":"2530449","id":"PMC_2530449","title":"Enhanced O6-methylguanine-DNA methyltransferase activity in transgenic mice containing an integrated E. coli ada repair gene.","date":"1989","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/2530449","citation_count":28,"is_preprint":false},{"pmid":"15824526","id":"PMC_15824526","title":"Tuberculous effusion: ADA activity correlates with CD4+ cell numbers in the fluid and the pleura.","date":"2005","source":"Respiration; international review of thoracic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/15824526","citation_count":28,"is_preprint":false},{"pmid":"38688902","id":"PMC_38688902","title":"A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38688902","citation_count":27,"is_preprint":false},{"pmid":"36309141","id":"PMC_36309141","title":"Zinc normalizes hepatic lipid handling via modulation of ADA/XO/UA pathway and caspase 3 signaling in highly active antiretroviral therapy-treated Wistar rats.","date":"2022","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/36309141","citation_count":27,"is_preprint":false},{"pmid":"28351939","id":"PMC_28351939","title":"Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28351939","citation_count":27,"is_preprint":false},{"pmid":"9383376","id":"PMC_9383376","title":"Metal-coordination sphere in the methylated Ada protein-DNA co-complex.","date":"1994","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/9383376","citation_count":26,"is_preprint":false},{"pmid":"2843522","id":"PMC_2843522","title":"Activation of Ada protein as a transcriptional regulator by direct alkylation with methylating agents.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2843522","citation_count":26,"is_preprint":false},{"pmid":"32880085","id":"PMC_32880085","title":"Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry.","date":"2020","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32880085","citation_count":25,"is_preprint":false},{"pmid":"21570366","id":"PMC_21570366","title":"The ada operon of Mycobacterium tuberculosis encodes two DNA methyltransferases for inducible repair of DNA alkylation damage.","date":"2011","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/21570366","citation_count":25,"is_preprint":false},{"pmid":"26263547","id":"PMC_26263547","title":"Spt-Ada-Gcn5-Acetyltransferase (SAGA) Complex in Plants: Genome Wide Identification, Evolutionary Conservation and Functional Determination.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26263547","citation_count":25,"is_preprint":false},{"pmid":"17287605","id":"PMC_17287605","title":"ADA*2 allele of the adenosine deaminase gene may protect against coronary artery disease.","date":"2007","source":"Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/17287605","citation_count":25,"is_preprint":false},{"pmid":"3041376","id":"PMC_3041376","title":"Rapid, large-scale purification and characterization of 'Ada protein' (O6 methylguanine-DNA methyltransferase) of E. coli.","date":"1988","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/3041376","citation_count":25,"is_preprint":false},{"pmid":"30488729","id":"PMC_30488729","title":"2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 - PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies' inputs on bioanalysis, biomarkers and immunogenicity).","date":"2018","source":"Bioanalysis","url":"https://pubmed.ncbi.nlm.nih.gov/30488729","citation_count":24,"is_preprint":false},{"pmid":"2505068","id":"PMC_2505068","title":"Cloning and expression of the Bacillus subtilis methyltransferase gene in Escherichia coli ada- cells.","date":"1989","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/2505068","citation_count":24,"is_preprint":false},{"pmid":"11284682","id":"PMC_11284682","title":"Structural basis for the functional switch of the E. coli Ada protein.","date":"2001","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11284682","citation_count":24,"is_preprint":false},{"pmid":"2407342","id":"PMC_2407342","title":"High level, regulated expression of the chimeric P-enolpyruvate carboxykinase (GTP)-bacterial O6-alkylguanine-DNA alkyltransferase (ada) gene in transgenic mice.","date":"1990","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/2407342","citation_count":24,"is_preprint":false},{"pmid":"3985005","id":"PMC_3985005","title":"Adenosine deaminase (ADA) in leukemia: clinical value of plasma ADA activity and characterization of leukemic cell ADA.","date":"1985","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/3985005","citation_count":24,"is_preprint":false},{"pmid":"12435054","id":"PMC_12435054","title":"Advances in gene therapy for ADA-deficient SCID.","date":"2002","source":"Current opinion in molecular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/12435054","citation_count":23,"is_preprint":false},{"pmid":"8468304","id":"PMC_8468304","title":"The Ada protein is a class I transcription factor of Escherichia coli.","date":"1993","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/8468304","citation_count":22,"is_preprint":false},{"pmid":"31365139","id":"PMC_31365139","title":"Effect of quercetin on E-NTPDase/E-ADA activities and cytokine secretion of complete Freund adjuvant-induced arthritic rats.","date":"2019","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/31365139","citation_count":22,"is_preprint":false},{"pmid":"2054779","id":"PMC_2054779","title":"Enhanced repair of O6-methylguanine DNA adducts in the liver of transgenic mice expressing the ada gene.","date":"1991","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/2054779","citation_count":21,"is_preprint":false},{"pmid":"21640091","id":"PMC_21640091","title":"Analysis of serum adenosine deaminase (ADA) and ADA1 and ADA2 isoenzyme activities in HIV positive and HIV-HBV co-infected patients.","date":"2011","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21640091","citation_count":21,"is_preprint":false},{"pmid":"30093511","id":"PMC_30093511","title":"Evaluation of ADA HbA1c criteria in the diagnosis of pre-diabetes and diabetes in a population of Chinese adolescents and young adults at high risk for diabetes: a cross-sectional study.","date":"2018","source":"BMJ open","url":"https://pubmed.ncbi.nlm.nih.gov/30093511","citation_count":21,"is_preprint":false},{"pmid":"24509845","id":"PMC_24509845","title":"DNA binding by Sgf11 protein affects histone H2B deubiquitination by Spt-Ada-Gcn5-acetyltransferase (SAGA).","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24509845","citation_count":20,"is_preprint":false},{"pmid":"38029911","id":"PMC_38029911","title":"3D bioprinting of multifunctional alginate dialdehyde (ADA)-gelatin (GEL) (ADA-GEL) hydrogels incorporating ferulic acid.","date":"2023","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38029911","citation_count":20,"is_preprint":false},{"pmid":"17852820","id":"PMC_17852820","title":"Pleural fluid ADA, IgA-ELISA and PCR sensitivities for the diagnosis of pleural tuberculosis.","date":"2007","source":"Scandinavian journal of clinical and laboratory investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17852820","citation_count":20,"is_preprint":false},{"pmid":"10036850","id":"PMC_10036850","title":"The dental team and latex hypersensitivity. ADA Council on Scientific Affairs.","date":"1999","source":"Journal of the American Dental Association (1939)","url":"https://pubmed.ncbi.nlm.nih.gov/10036850","citation_count":19,"is_preprint":false},{"pmid":"31871959","id":"PMC_31871959","title":"Dosing and Re-Administration of Lentiviral Vector for In Vivo Gene Therapy in Rhesus Monkeys and ADA-Deficient Mice.","date":"2019","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/31871959","citation_count":19,"is_preprint":false},{"pmid":"3058696","id":"PMC_3058696","title":"Proteolytic cleavage of Ada protein that carries methyltransferase and transcriptional regulator activities.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3058696","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50547,"output_tokens":7204,"usd":0.129851,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16643,"output_tokens":5203,"usd":0.106645,"stage2_stop_reason":"end_turn"},"total_usd":0.236496,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"The E. coli Ada protein (38–39 kDa) transfers methyl groups from O6-methylguanine residues in alkylated DNA to its own cysteine residues, functioning as a suicidal methyltransferase; the protein comprises 354 amino acids and the promoter was mapped by S1 nuclease.\",\n      \"method\": \"Protein purification, in vitro methyltransferase assay, DNA sequencing, S1 nuclease mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro biochemical reconstitution of methyl-transfer activity with purified protein, replicated across multiple studies\",\n      \"pmids\": [\"2987251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"Ada protein acts as a positive autogenous regulator: cloned ada gene product induces expression of O6-methylguanine-DNA methyltransferase and 3-methyladenine-DNA glycosylase II even without alkylating agent treatment, and induction is strongly enhanced by methylating agents, demonstrating that the methylated Ada protein promotes transcription of its own gene.\",\n      \"method\": \"Cloning in multicopy plasmids, beta-galactosidase reporter (ada'-lacZ fusion), enzyme activity assays in vivo\",\n      \"journal\": \"Mutation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and reporter-based evidence replicated across labs; Ada protein's transcriptional activator role independently confirmed\",\n      \"pmids\": [\"3929077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1982,\n      \"finding\": \"The ada mutation is in a regulatory locus controlling O6-methylguanine-DNA methyltransferase induction; ada mutants contain basal methyltransferase but cannot upregulate it upon alkylation treatment, showing Ada is required for the adaptive transcriptional response.\",\n      \"method\": \"In vitro enzyme assay with synthetic radiolabeled DNA substrate, comparison of wild-type and ada mutant strains\",\n      \"journal\": \"Journal of bacteriology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic loss-of-function with quantitative enzyme assay, single study\",\n      \"pmids\": [\"6749819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Methylation of Ada protein at Cys-69 (by methyl phosphotriester transfer) converts Ada into a transcriptional activator; direct methylation of purified Ada protein by chemical methylating agents (methyl methanesulfonate, methyl iodide) also activates its ability to promote ada gene transcription in a reconstituted in vitro system.\",\n      \"method\": \"In vitro transcription reconstitution with purified methylated/unmethylated Ada protein\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified components demonstrating methylation-dependent transcriptional activation\",\n      \"pmids\": [\"2843522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Ada protein expression is controlled by an ada regulatory sequence (AAAGCGCA) located upstream of the -35 box; both -10 and -35 promoter elements and this regulatory sequence are required for controlled ada expression. Methylated Ada protein is required for in vitro ada-specific transcription.\",\n      \"method\": \"Random and site-directed mutagenesis of ada promoter, deletion analysis, in vitro transcription\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis combined with in vitro transcription reconstitution\",\n      \"pmids\": [\"3139888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Ada protein is cleaved by an endogenous E. coli thiol protease into a 20-kDa N-terminal fragment (which retains methylphosphotriester methyltransferase activity and can promote alkA but not ada transcription when methylated) and a 19-kDa C-terminal fragment (which retains O6-methylguanine methyltransferase activity); neither fragment alone promotes ada transcription.\",\n      \"method\": \"Partial purification of Ada-specific protease, proteolysis assay, activity assays on isolated fragments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical dissection of domain function with purified fragments and in vitro activity assays\",\n      \"pmids\": [\"3058696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Methylated Ada protein binds the ada promoter (positions -63 to -31) including the AAAGCGCA regulatory sequence; non-methylated Ada does not bind stably. Methylation of Cys-69 (not Cys-321) is specifically required for Ada binding to the ada promoter and for facilitating subsequent RNA polymerase binding. The methylated Ada protein also allows RNA polymerase to bind properly, initiating transcription.\",\n      \"method\": \"DNase I footprinting, in vitro transcription with site-specific Ada mutants (Cys69Ala, Cys321Ala), promoter mutant analysis\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — footprinting + site-directed mutagenesis + in vitro transcription reconstitution in a single study\",\n      \"pmids\": [\"2648001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The methylated 20-kDa N-terminal Ada fragment binds the alkA regulatory sequence and facilitates RNA polymerase binding to the alkA promoter, activating alkA transcription in vitro. The same methylated 20-kDa protein binds the ada promoter but does not support RNA polymerase binding there, thus acting as a repressor of ada transcription. Proteolytic cleavage of Ada terminates the adaptive response by removing the activator and generating a repressor.\",\n      \"method\": \"Overexpression of truncated Ada, in vitro transcription, in vivo reporter assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution plus in vivo confirmation, mechanistic model for adaptive response termination\",\n      \"pmids\": [\"2254928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Ada protein binds DNA non-cooperatively; approximately 7 bp are covered per Ada monomer; binding is ionic in nature (equilibrium association constant decreases with increasing NaCl), as measured by fluorescence anisotropy.\",\n      \"method\": \"Fluorescence anisotropy of Ada protein upon DNA binding; quantitative binding analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous biophysical assay on purified protein, single lab\",\n      \"pmids\": [\"2354146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Methylated Ada protein is a class I transcription factor: it requires the C-terminal domain of the RNA polymerase alpha subunit for transcriptional activation, as demonstrated by loss of Ada-dependent activation with C-terminal-deleted alpha subunit mutant RNA polymerases.\",\n      \"method\": \"In vitro transcription with mutant RNA polymerases bearing C-terminal-deleted alpha subunits\",\n      \"journal\": \"Journal of bacteriology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro transcription with defined mutant components, clear mechanism\",\n      \"pmids\": [\"8468304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Crystal structure of the 19-kDa C-terminal domain of E. coli Ada (Ada-C), the O6-methylguanine-DNA methyltransferase domain, shows the active-site cysteine is buried; a conformational change is proposed to allow DNA binding and methyl transfer.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with atomic resolution; functionally validated by comparison with known mutant phenotypes\",\n      \"pmids\": [\"8156986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Unmethylated Ada at physiologically relevant concentrations specifically inhibits methylated Ada activation of ada transcription (but not alkA transcription) both in vitro and in vivo; this requires the C-terminal 67 amino acids of Ada. This establishes Ada as both a positive and negative modulator of its own expression.\",\n      \"method\": \"In vitro transcription assay, in vivo reporter assays, C-terminal deletion mutants of Ada\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro and in vivo concordance, defined domain requirement, single lab\",\n      \"pmids\": [\"7937881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"In the methylated Ada protein–DNA complex, S-methylcysteine-69 (S-Me-Cys69) remains coordinated to the zinc ion; ligand exchange at the zinc center is not the mechanism for switching Ada from repair to transcriptional activator mode.\",\n      \"method\": \"Isotope-edited NMR (13C-labeled methyl group at Cys69), comparison of Zn- and Cd-substituted forms\",\n      \"journal\": \"Chemistry & biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural analysis with isotopic labeling, clear mechanistic conclusion, single lab\",\n      \"pmids\": [\"9383376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Ada protein-dependent transcriptional activation at the ada and aidB promoters requires direct interaction between methylated Ada and the C-terminal domain of the RNA polymerase sigma70 subunit (amino acids 574–613); several negatively charged residues in sigma70 (notably Glu575) are critical. The alpha subunit C-terminal domain allows initial RNA polymerase binding, while sigma70 interaction drives activation.\",\n      \"method\": \"Deletion mutagenesis of RNA polymerase alpha and sigma subunits, in vitro transcription, site-directed mutagenesis of sigma70\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — defined protein–protein contact by mutagenesis plus functional in vitro transcription, multiple orthogonal approaches\",\n      \"pmids\": [\"9582376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"E. coli Ada-C protein can repair O6-benzylguanine in DNA, but very slowly compared to human alkyltransferase and E. coli Ogt; two active-site mutations (A316P and W336A) that enlarge the substrate-binding pocket of Ada-C greatly increase its reactivity with O6-benzylguanine, and DNA binding activates Ada-C for this reaction.\",\n      \"method\": \"Site-directed mutagenesis, in vitro alkyltransferase assay, substrate competition experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — active-site mutagenesis + in vitro assay with defined substrates, mechanistic interpretation of steric factors\",\n      \"pmids\": [\"9079656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NMR solution structure of the N-terminal 10-kDa Ada domain (N-Ada10) reveals the zinc-thiolate center; EXAFS/XANES data confirm that S-Me-Cys69 remains coordinated to zinc upon methylation. The transferred methyl group makes contacts within N-Ada but not with DNA, implying that methylation induces a conformational change that remodels the protein surface to enhance promoter DNA binding without direct methyl-DNA contact.\",\n      \"method\": \"NMR structure determination, EXAFS/XANES spectroscopy, NOESY of labeled methylated Ada–DNA complexes\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal structural methods (NMR + X-ray absorption spectroscopy) in one study with functional interpretation\",\n      \"pmids\": [\"11284682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"X-ray and solution structures of the methylated N-terminal Ada chemosensor domain bound to DNA reveal that methyl phosphotriester repair and methylation-dependent transcriptional activation both operate through a zinc- and methylation-dependent electrostatic switch: methylation of Cys69 neutralizes a negative charge at the zinc center, converting a repulsive to an attractive interaction with DNA phosphates, thereby switching Ada from a repair protein to a transcriptional activator.\",\n      \"method\": \"X-ray crystallography and NMR of methylated N-Ada–DNA complex; functional validation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution structure with functional validation provides mechanistic model for the electrostatic switch\",\n      \"pmids\": [\"16209950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"In yeast, Gcn5 (which contains Ada protein homologs as subunits) functions as the catalytic histone acetyltransferase subunit in two distinct native complexes: the 0.8-MDa ADA complex and the 1.8-MDa SAGA complex. Both complexes contain Ada2 and can acetylate nucleosomal histones, unlike recombinant Gcn5 alone. The SAGA complex additionally contains Spt proteins linked to TBP function.\",\n      \"method\": \"Biochemical fractionation, histone acetyltransferase assays on free and nucleosomal histones, deletion mutant analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical reconstitution of HAT complexes with functional nucleosomal HAT assay; foundational study replicated by multiple labs\",\n      \"pmids\": [\"9224714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Mutations in yeast ADA2, ADA3, and GCN5 (subunits of the Ada/histone acetyltransferase complex) cause phenotypes similar to swi/snf mutants and are required for expression of SWI/SNF-dependent genes; ada and swi1 double mutants are inviable; SIN1 mutations (chromatin component) or histone H3/H4 mutations partially suppress ada/swi defects, establishing that ADA/GCN5 and SWI/SNF complexes cooperate to antagonize chromatin-mediated repression.\",\n      \"method\": \"Yeast genetics, epistasis analysis, double mutant viability, partial purification of three GCN5-dependent acetyltransferase activities\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis across multiple loci plus biochemical acetyltransferase assays, replicated findings\",\n      \"pmids\": [\"9343382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Tra1p is a component of yeast Ada/Spt transcriptional regulatory complexes; its association with Ada.Spt complexes was established by tandem mass spectrometry of Ngg1p/Ada3p co-purified proteins and confirmed by reciprocal co-immunoprecipitation of Ada2p and Tra1p. Tra1p co-fractionates with Ngg1p and Spt7p; binding of Tra1p to DNA-cellulose requires Ada components.\",\n      \"method\": \"Tandem mass spectrometry, reciprocal co-immunoprecipitation, sequential chromatography\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus MS identification, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"9756893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The yeast ADA complex (0.8 MDa) is a distinct histone acetyltransferase complex separate from SAGA, containing Ada2, Ada3, Gcn5, and a novel unique subunit Ahc1 (product of YOR023C); deletion of AHC1 disrupts ADA complex integrity without affecting SAGA, demonstrating that ADA is not merely a SAGA subcomplex.\",\n      \"method\": \"10-step chromatographic purification, mass spectrometry, immunoblotting, deletion mutant analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — extensive biochemical purification combined with MS identification and genetic validation\",\n      \"pmids\": [\"10490601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The yeast Ada adaptor complex is important for glucocorticoid receptor (GR)-mediated gene activation; Ada2 directly binds the GR tau1c transactivation domain in vitro using purified proteins and GST-pulldown, and this interaction is reduced by a mutation that reduces tau1c transactivation.\",\n      \"method\": \"Yeast genetics (ada mutant phenotype), GST pulldown with purified proteins, in vitro protein-protein interaction\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein interaction confirmed with purified proteins, functional genetic data, single lab\",\n      \"pmids\": [\"9154805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In yeast, GCN5, ADA2, ADA1, and ADA3 are required for T3/GRIP1 or SRC-1 coactivator-dependent transcriptional activation by human thyroid hormone receptor beta1 (hTRbeta1); hTRbeta1 binds directly to yeast or human GCN5 and to hADA2 in vitro; T3-dependent binding of hTRbeta1 to hGCN5 is enhanced by GRIP1 or SRC-1. The HAT domain and bromodomain of GCN5 must be intact for maximal activation.\",\n      \"method\": \"Yeast genetic epistasis, in vitro protein-protein interaction (GST pulldown with purified proteins), mutagenesis of GRIP1 LXXLL motifs\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast genetics plus direct protein binding with purified proteins, single lab\",\n      \"pmids\": [\"10809234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In metazoans, GCN5 is incorporated into two distinct HAT complexes: ATAC (containing ADA2a) and SAGA (containing ADA2b). The subunit environment determines GCN5 catalytic activity: all tested GCN5-containing complexes acetylate mainly histone H3K14, but ADA2b has a stronger stimulatory influence on GCN5 activity than ADA2a. Incorporation into holo-complexes further increases GCN5 activity beyond the HAT module alone.\",\n      \"method\": \"In vitro HAT assay with purified recombinant and endogenous ATAC/SAGA HAT modules and holo-complexes using histone peptides and full-length histones\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified recombinant complexes and multiple substrates, single lab but multiple orthogonal readouts\",\n      \"pmids\": [\"26468280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The SAGA complex adopts three major conformations; the acetyltransferase module is localized in the most mobile region. Cross-linking mass spectrometry mapped comprehensive subunit interconnectivity, showing that Spt and Taf subunits form the structural core, and chromatin-binding domains cluster on one flexible face.\",\n      \"method\": \"Gradient fixation, single-particle EM (2D and 3D), EM-based subunit labeling, cross-linking mass spectrometry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structural analysis plus cross-linking MS, multiple orthogonal methods in one study\",\n      \"pmids\": [\"25713136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In ADA-deficient mice, Tregs show alterations in plasma membrane CD39/CD73 ectonucleotidase machinery and have limited suppressive activity via extracellular adenosine; ADA deficiency causes loss of Treg function contributing to autoimmunity. PEG-ADA-treated mice develop autoantibodies and hypothyroidism and have Tregs lacking suppressive activity, whereas bone marrow transplantation or gene therapy corrects Treg function.\",\n      \"method\": \"Functional Treg suppression assays, flow cytometry, mouse genetic models (ADA-/- mice), treatment comparisons (PEG-ADA, BMT, gene therapy)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional suppression assays in defined genetic model with multiple therapeutic comparisons, single lab\",\n      \"pmids\": [\"22184407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ADA deficiency in mice causes a bone phenotype resulting from RANKL/OPG axis imbalance (decreased osteoclastogenesis) and intrinsic osteoblast dysfunction (reduced bone formation); ADA-deficient osteoblasts in vitro show altered transcriptional profile and growth reduction. Treatment with ERT, BMT, or gene therapy fully rescues the bone phenotype.\",\n      \"method\": \"Mouse genetic model (ADA-/- mice), structural bone analysis, in vitro osteoblast culture, RANKL/OPG quantification, treatment rescue experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined genetic model with in vitro mechanistic follow-up and multiple treatment rescues, single lab\",\n      \"pmids\": [\"19633200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In ADA-SCID patients, ADA substrate accumulation causes impaired TCR/CD28-driven T-cell proliferation and cytokine production associated with reduced ZAP-70 phosphorylation, Ca2+ flux, and ERK1/2 signaling, and defective CREB and NF-κB transcriptional activity. Exposure to 2'-deoxyadenosine further inhibits T-cell activation via A2A adenosine receptor/PKA hyperactivation. Gene therapy restores normal TCR signaling in patient T cells.\",\n      \"method\": \"Phosphoprotein analysis, calcium flux assay, cytokine measurement, patient T cells vs. gene-therapy-corrected T cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient-derived cells with multiple signaling readouts and gene-therapy correction as functional rescue, single lab\",\n      \"pmids\": [\"18218852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In ADA-deficient mice, metabolic alterations in the brain include aberrant adenosine receptor signaling; PEG-ADA corrects metabolic adenosine-based alterations but not cellular and signaling defects, indicating an intrinsic neurological component to ADA deficiency separate from circulating adenosine levels.\",\n      \"method\": \"Behavioral testing, molecular/metabolic analyses, treatment with PEG-ADA vs. untreated ADA-/- mice\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mouse genetic model with molecular mechanistic analysis, single lab\",\n      \"pmids\": [\"28074903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The B. subtilis ada operon encodes two separate DNA alkyltransferases: AdaA (methylphosphotriester-DNA methyltransferase) functioning as a transcriptional activator of the ada operon, and AdaB (O6-methylguanine-DNA methyltransferase) functioning specifically in repair of mutagenic O6-methylguanine; the two genes overlap by 11 bp and are co-induced by MNNG.\",\n      \"method\": \"Complementation of ada mutants, gene cloning, transcript analysis, functional dissection of truncated constructs\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic complementation with functional domain analysis; describes bacterial ortholog mechanism\",\n      \"pmids\": [\"2120677\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"The E. coli Ada protein is a bifunctional enzyme and transcriptional regulator of the adaptive response to alkylating agents: its C-terminal domain irreversibly transfers methyl groups from O6-methylguanine in DNA to Cys-321, while its N-terminal domain transfers methyl from methylphosphotriesters to Cys-69; methylation at Cys-69 triggers an electrostatic switch—maintaining zinc-thiolate coordination but remodeling a surface patch—that converts Ada into a sequence-specific transcriptional activator that binds the ada/alkA promoters and recruits RNA polymerase through direct contact with the sigma70 C-terminal domain, while unmethylated Ada and a proteolytic 20-kDa fragment act as negative regulators to terminate the response; in eukaryotes, the orthologous ADA complex subunits (Ada2, Ada3) scaffold the GCN5 histone acetyltransferase within the ADA and SAGA co-activator complexes to acetylate nucleosomal histone H3K14 and mediate transcriptional activation by nuclear receptors, with complex-specific ADA2 isoforms (ADA2a in ATAC, ADA2b in SAGA) differentially stimulating GCN5 catalytic activity; in humans, ADA enzymatic activity (deamination of adenosine and deoxyadenosine) is essential for lymphocyte survival, and its deficiency causes toxic purine metabolite accumulation that impairs TCR signaling, Treg function via the CD39/CD73/adenosine axis, bone homeostasis via RANKL/OPG imbalance, and brain adenosine receptor signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"The ADA symbol in this corpus resolves into three biologically distinct proteins, and the timeline is dominated by the bacterial Ada DNA-alkylation-repair regulator rather than the human adenosine deaminase. The E. coli Ada protein is a bifunctional suicide methyltransferase that, in its repair role, irreversibly transfers methyl groups from O6-methylguanine in alkylated DNA to its own cysteine residues [#0], with the active-site cysteine buried in the 19-kDa C-terminal domain whose structure has been solved [#10]. A second methyltransferase activity in the N-terminal domain accepts methyl from methylphosphotriesters at Cys-69, and this specific modification—not the C-terminal Cys-321 methylation—converts Ada into a sequence-specific transcriptional activator of the adaptive response to alkylating agents [#3, #6]. Methylated Ada binds the ada/alkA regulatory sequence (AAAGCGCA) upstream of the promoter and recruits RNA polymerase through direct contact with the C-terminal domain of the alpha subunit and with the C-terminal region of sigma70 (notably Glu575), defining Ada as a class I activator [#4, #9, #13]. The repair-to-activator switch is electrostatic rather than ligand-exchange-based: structural and spectroscopic analyses show S-methyl-Cys69 remains zinc-coordinated, and neutralization of negative charge at the zinc-thiolate center remodels a surface patch to convert phosphate repulsion into attraction for promoter DNA [#12, #15, #16]. The response is self-limiting: unmethylated Ada antagonizes its own activation [#11], and an endogenous protease cleaves Ada into a 20-kDa N-terminal fragment that activates alkA but represses ada, terminating the adaptive response [#5, #7]. A separate set of findings describes the eukaryotic ADA/Ada2/Ada3 transcriptional co-activator subunits, which scaffold the GCN5 histone acetyltransferase within the ADA and SAGA complexes to acetylate nucleosomal histone H3K14, antagonize chromatin-mediated repression together with SWI/SNF, and mediate activation by nuclear receptors, with complex-specific ADA2 isoforms (ATAC ADA2a vs SAGA ADA2b) differentially stimulating GCN5 [#17, #18, #23]. A third set addresses human ADA enzymatic activity, whose deficiency causes toxic purine accumulation impairing TCR signaling [#27], Treg suppressive function via the CD39/CD73/adenosine axis [#25], bone homeostasis via RANKL/OPG imbalance [#26], and brain adenosine receptor signaling [#28]. These three groups describe unrelated proteins sharing the ADA/Ada symbol.\",\n  \"teleology\": [\n    {\n      \"year\": 1982,\n      \"claim\": \"Established that Ada is a regulatory locus required for the inducible adaptive response, not merely the repair enzyme itself, since ada mutants retain basal methyltransferase but cannot upregulate it.\",\n      \"evidence\": \"In vitro enzyme assay on radiolabeled DNA comparing wild-type and ada mutant E. coli strains\",\n      \"pmids\": [\"6749819\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Did not define the molecular activity of the Ada gene product\", \"Single genetic study without biochemical mechanism\"]\n    },\n    {\n      \"year\": 1985,\n      \"claim\": \"Defined Ada as a suicidal methyltransferase that transfers methyl from O6-methylguanine to its own cysteines, identifying the repair chemistry and protein.\",\n      \"evidence\": \"Protein purification, in vitro methyltransferase assay, DNA sequencing and S1 mapping in E. coli\",\n      \"pmids\": [\"2987251\", \"3929077\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Did not resolve which cysteine accepts which methyl group\", \"Mechanism linking methylation to transcription not established\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Showed that methylation of Cys-69 by methylphosphotriester transfer—reproducible with chemical methylating agents—converts Ada into a transcriptional activator, mechanistically coupling DNA damage sensing to gene induction.\",\n      \"evidence\": \"In vitro transcription reconstitution and promoter mutagenesis with purified methylated/unmethylated Ada\",\n      \"pmids\": [\"2843522\", \"3139888\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Direct DNA binding by methylated Ada not yet demonstrated\", \"RNA polymerase contacts undefined\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Demonstrated that methylated Ada binds the ada promoter regulatory sequence and facilitates RNA polymerase binding, and that Cys-69 (not Cys-321) methylation is specifically required, separating the repair and regulatory functions.\",\n      \"evidence\": \"DNase I footprinting and in vitro transcription with Cys69Ala/Cys321Ala site-directed mutants\",\n      \"pmids\": [\"2648001\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Biophysical nature of DNA binding not quantified\", \"Specific RNA polymerase subunit contacts not mapped\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Established the self-limiting architecture of the response: proteolytic cleavage removes the ada activator and generates a 20-kDa fragment that activates alkA but represses ada, terminating the adaptive response; DNA binding was also characterized biophysically.\",\n      \"evidence\": \"Truncated Ada overexpression, in vitro transcription, in vivo reporters, and fluorescence anisotropy DNA-binding analysis\",\n      \"pmids\": [\"2254928\", \"2354146\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Identity and regulation of the endogenous protease not fully defined\", \"Structural basis of differential ada vs alkA promoter behavior unresolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Refined the regulatory logic by showing unmethylated Ada antagonizes methylated-Ada activation of ada (requiring the C-terminal 67 residues), establishing Ada as both positive and negative modulator of its own expression.\",\n      \"evidence\": \"In vitro and in vivo transcription assays with C-terminal deletion mutants of Ada\",\n      \"pmids\": [\"7937881\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Structural basis of the inhibitory interaction not defined\", \"Promoter-specificity of inhibition mechanism unexplained\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identified Ada as a class I transcription factor requiring the RNA polymerase alpha C-terminal domain, then mapped a direct activating contact with the sigma70 C-terminal region (Glu575), defining the activation interface.\",\n      \"evidence\": \"In vitro transcription with alpha- and sigma-subunit deletion and point mutants\",\n      \"pmids\": [\"8468304\", \"9582376\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Atomic structure of the Ada–RNA polymerase contact not solved\", \"Stoichiometry of the activation complex unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Resolved the switch mechanism structurally, showing methylated Cys-69 remains zinc-coordinated and that ligand exchange at zinc is not the switch, and solved the C-terminal repair domain structure revealing a buried active-site cysteine.\",\n      \"evidence\": \"Isotope-edited NMR of 13C-methyl-Cys69, Zn/Cd substitution, and X-ray crystallography of Ada-C\",\n      \"pmids\": [\"9383376\", \"8156986\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"How surface remodeling enables DNA binding not yet visualized\", \"Conformational change enabling repair-domain DNA access only proposed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Characterized the repair domain's substrate determinants, showing active-site steric mutations (A316P, W336A) expand reactivity toward O6-benzylguanine and that DNA binding activates Ada-C.\",\n      \"evidence\": \"Active-site site-directed mutagenesis and in vitro alkyltransferase assays with defined substrates\",\n      \"pmids\": [\"9079656\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Physiological relevance of expanded substrate range unaddressed\", \"Coupling of DNA binding to catalysis not structurally resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Provided the definitive electrostatic-switch model: structures of methylated N-Ada bound to DNA show Cys69 methylation neutralizes negative charge at the zinc center, converting phosphate repulsion to attraction and unifying repair and transcriptional functions.\",\n      \"evidence\": \"X-ray and NMR structures of methylated N-Ada–DNA complex with EXAFS/XANES and functional validation\",\n      \"pmids\": [\"16209950\", \"11284682\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Full-length Ada–promoter–RNA polymerase assembly structure not determined\", \"Dynamics of the surface remodeling not characterized\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that eukaryotic Ada2/Ada3 subunits scaffold GCN5 into distinct nucleosome-acetylating complexes (ADA and SAGA), conferring nucleosomal HAT activity absent in free GCN5 and revealing ADA as a bona fide separate complex via the Ahc1 subunit.\",\n      \"evidence\": \"Biochemical fractionation, nucleosomal HAT assays, MS identification, and deletion analysis in yeast\",\n      \"pmids\": [\"9224714\", \"10490601\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"These findings concern a distinct protein from bacterial Ada sharing the symbol\", \"Mechanism by which Ada subunits stimulate GCN5 not defined here\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Linked the ADA/GCN5 co-activator subunits to chromatin antagonism with SWI/SNF and to nuclear receptor activation (glucocorticoid and thyroid hormone receptors) through direct Ada2/GCN5 contacts.\",\n      \"evidence\": \"Yeast genetic epistasis, GST pulldowns with purified proteins, and HAT assays\",\n      \"pmids\": [\"9343382\", \"9154805\", \"10809234\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Direct receptor-Ada2 interactions shown in single labs\", \"Concerns the eukaryotic ADA co-activator, distinct from bacterial Ada and human adenosine deaminase\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined how metazoan complex context tunes GCN5: ATAC (ADA2a) and SAGA (ADA2b) both target H3K14 but ADA2b stimulates GCN5 more strongly, and holo-complex incorporation further boosts activity, with SAGA architecture mapped structurally.\",\n      \"evidence\": \"In vitro HAT assays with reconstituted modules/holo-complexes and cryo-EM plus cross-linking MS\",\n      \"pmids\": [\"26468280\", \"25713136\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Mechanism of differential ADA2a vs ADA2b stimulation not structurally resolved\", \"Distinct protein from the human adenosine deaminase ADA\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established the physiological consequences of human ADA enzymatic deficiency across systems—T-cell receptor signaling, Treg suppressive function, bone homeostasis, and brain adenosine signaling—via toxic purine/adenosine accumulation.\",\n      \"evidence\": \"ADA-deficient mouse models and patient-derived T cells with signaling, suppression, bone, and metabolic readouts plus therapeutic rescue (ERT/BMT/gene therapy)\",\n      \"pmids\": [\"18218852\", \"22184407\", \"19633200\", \"28074903\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"These describe human adenosine deaminase, a distinct enzyme from the bacterial/eukaryotic Ada in this corpus\", \"Intrinsic versus adenosine-mediated contributions only partially separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the full bacterial Ada–promoter–RNA polymerase activation complex is structurally assembled and how the surface electrostatic switch is communicated to the holoenzyme; the corpus also conflates three distinct ADA/Ada proteins.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"No atomic structure of the activator-bound transcription initiation complex\", \"Symbol collision among bacterial Ada repair regulator, eukaryotic ADA co-activator subunit, and human adenosine deaminase\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [0, 5, 10, 14]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 3, 5]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [6, 8, 16]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 3, 6, 9]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [17, 23]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 10]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 6, 9, 13]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [17, 18, 23]}\n    ],\n    \"complexes\": [\"SAGA\", \"ADA complex\", \"ATAC\"],\n    \"partners\": [\"GCN5\", \"ADA2\", \"ADA3\", \"Tra1\", \"Spt7\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"loss","faith_supported":7,"faith_total":7,"faith_pct":100.0}}